The possible side effects of Vyndamax include bloating due to fluid buildup in the legs or arms, decreased sense of touch or numbness, breathing problems or wheezing, racing heart, swollen lymph nodes and fever or general ill feeling.
Most people taking Vyndamax don't experience side effects.
Once you begin taking Vyndamax it takes as long as 6 months for Vyndamax to fully work and see noticeable improvements in your symptoms.
You should begin seeing noticeable improvements in your symptoms like physical capacity and shortness of breath within 6 months of beginning Vyndamax.
The full effects of Vyndamax may continue to develop over a longer period, although the Vyndamax drug begins working as soon as you start taking it to stabilize the transthyretin protein.
And you should start to feel or see positive changes around the 6th month mark of beginning Vyndamax.
You can take Vyndamax any time of day with or without food once a day.
It doesn't really matter what time of day you take Vyndamax as long as you take it once a day.
Vyndamax is usually taken as 1 capsule once a day, if you're taking Vyndaqel also known as tafamidis it is usually given as 4 capsules once a day.
Also take tafamidis at around the same time every day.
Do not take Vyndamax and Vyndaqel at the same time.
The life expectancy of someone on Vyndamax is around 5 years, although some people may survive longer on Vyndamax.
Vyndamax itself does not have a definitive life expectancy as it treats transthyretin amyloid cardiomyopathy, which is a progressive and fatal disease, although studies show that Vyndamax can improve survival when compared to no treatment.
Data shows a preliminary 5 year survival rate of 53.2 percent in people who received continuous treatment with Vyndamax although some may die as soon as 4 years.
Vyndamax has been on the market since May of 2019.
The U.S. Food and Drug Administration also known as the FDA approved Vyndamax for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Vyndamax was approved around the same time as a similar formulated drug called Vyndaqel, although Pfizer planned to transition any patients to the single capsule Vyndamax, which then became available in the latter half of the year 2019.
The list price for the drug Vyndamax is over $21,800.00 per month, although the out-of-pocket cost can also vary significantly based on your health insurance.
Commercially health insured patients may pay as little as $0 per month for Vyndamax through a co-pay savings program, while Medicare patients can have their annual out-of-pocket cost for Vyndamax capped at $2,000.00 for all their Part D medications.
Vyndamax is a prescription medicine that is used to treat adults with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce death and hospitalization related to heart problems.
Although it is not known if Vyndamax is safe and effective in children.
And two out of every five patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (Vyndamax and Vyndaqel; Pfizer) can be expected to die in less than 4 years.
Transthyretin amyloidosis (ATTR-CM) is a disease in which a misfolded protein, transthyretin (TTR), builds up as amyloid deposits in the heart muscle, causing it to become stiff and unable to pump blood effectively.
Symptoms of transthyretin amyloidosis (ATTR-CM) include shortness of breath, swelling in the legs and feet, fatigue, and an irregular heart rate.
Diagnosis for transthyretin amyloidosis (ATTR-CM) involves imaging and sometimes genetic testing, and treatment focuses on slowing disease progression through medication like tafamidis.